Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity

Highlights • KRAS mutations are the most common genetic event in lung adenocarcinoma. • The prognostic and predictive value of KRAS mutations is unclear. • Previous attempts to directly target KRAS have been unsuccessful. • A large number of novel agents and combinations are being currently evaluate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Critical reviews in oncology/hematology 2017-02, Vol.110, p.1-12
Hauptverfasser:	Matikas, Alexios, Mistriotis, Dimitrios, Georgoulias, Vasilios, Kotsakis, Athanasios
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Hematology, Oncology and Palliative Medicine Humans KRAS Lung Neoplasms - drug therapy Lung Neoplasms - genetics Medicin och hälsovetenskap MEK Mutation NSCLC Predictive Prognosis Prognostic Proto-Oncogene Proteins p21(ras) - genetics Targeted therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • KRAS mutations are the most common genetic event in lung adenocarcinoma. • The prognostic and predictive value of KRAS mutations is unclear. • Previous attempts to directly target KRAS have been unsuccessful. • A large number of novel agents and combinations are being currently evaluated
ISSN:	1040-8428 1879-0461 1879-0461
DOI:	10.1016/j.critrevonc.2016.12.005